Business Wire

Dole Food Company, Inc. Announces the Commencement of a Consent Solicitation for Its 7.25% Senior Secured Notes Due 2025

Del

Dole Food Company, Inc. (“Dole”) announced today the commencement of a consent solicitation regarding certain amendments (the “Amendments”) to the Indenture, dated as of April 6, 2017, among Dole, DFC Holdings, LLC (“Holdings”), as a guarantor, the subsidiary guarantors party thereto, and Wilmington Trust, National Association, as trustee (the “Trustee”), governing its 7.25% Senior Secured Notes due 2025 (the “Notes”) (the “Indenture”). Currently, the aggregate outstanding principal amount of Notes is $300,000,000.

The Amendments would release Holdings from its guarantee under the Indenture (and its other limited obligations under the Indenture and the Security Documents (as defined in the Indenture)), in each case, upon the consummation of a Qualified IPO (as defined in the Indenture) with respect to the common stock of the Issuer, and subject to the substantially concurrent (or prior) release of Holdings’ guarantees under the Term Loan Credit Agreement and Revolving Credit Agreement (each as defined in the Indenture).

The consent solicitation is conditioned upon the receipt of consents from holders of record as of June 23, 2017 of a majority in aggregate principal amount of the Notes (the “Requisite Consents”). The consent solicitation will expire at 5:00pm, New York City time, on July 6, 2017, unless extended (the “Expiration Date”).

Dole will, promptly after the Expiration Date and subject to the satisfaction or waiver of all conditions to the consent solicitation, pay to each holder of Notes who has delivered (and not revoked) a valid consent in favor of the Amendments a cash payment (the “Consent Fee”) of $2.50 for each $1,000 principal amount of Notes in respect of which such consent has been delivered.

The Amendments will be effected by, and will become effective upon, execution of a supplemental indenture. Dole proposes to execute the supplemental indenture as soon as practicable after obtaining the related Requisite Consents. At that time, the Amendments effected by the supplemental indenture will become effective and consents may no longer be revoked.

For a complete statement of the terms and conditions of the consent solicitations, holders of the Notes should refer to the Consent Solicitation Statement, dated June 26, 2017 (the “Consent Solicitation Statement”), which is being sent to all holders of the Notes as of the Record Date.

The Solicitation Agent in connection with the consent solicitation is Morgan Stanley & Co. LLC. Questions regarding the consent solicitation may be directed to Morgan Stanley & Co. LLC, Attention: Liability Management Group at (800) 624-1808 (toll free) or (212) 761-1057. Global Bondholder Services Corporation is serving as Information Agent and Tabulation Agent in connection with the consent solicitations. Requests for assistance in delivering consents or for additional copies of the consent solicitation statement should be directed to the Information Agent at (866) 470-3900 (toll free), (212) 430-3774 (banks and brokers) (collect) or contact@gbsc-usa.com.

This announcement is not an offer to purchase or a solicitation of an offer to purchase any securities. The consent solicitation is being made solely by the Consent Solicitation Statement and are subject to the terms and conditions stated therein.

This release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Forward-looking statements, which are based on management’s current expectations, are generally identifiable by the use of terms such as “may,” “will,” “expects,” “believes,” “intends,” “anticipates” and similar expressions. The potential risks and uncertainties that could cause actual results to differ materially from those expressed or implied herein include weather-related phenomena; market responses to industry volume pressures; product and raw materials supplies and pricing; energy supply and pricing; changes in interest and currency exchange rates; economic crises; security risks in developing countries; international conflict; and quotas, tariffs and other governmental actions. Further information on the factors that could affect Dole’s financial results is included in the Consent Solicitation Statement and the documents incorporated therein.

Contact information

Dole Food Company, Inc.
William Goldfield, 818-874-4647

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 07:06Pressemelding

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 07:00Pressemelding

Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53Pressemelding

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 14:59Pressemelding

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch